Treatment News : HIV Vaccine Based on Whole Virus Completes Phase I Trial

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » September 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


September 5, 2013

HIV Vaccine Based on Whole Virus Completes Phase I Trial

An HIV vaccine based on a genetically modified killed whole virus is the first of its kind to succeed in a Phase I clinical trial, proving safe, well tolerated and promising in its ability to elicit a sustained immune response, the Huffington Post reports. The vaccine, called SAV001-H, is the result of a collaboration between Western University in London, Ontario, and Sumagen Canada Inc. In a randomized, observer-blinded, placebo-controlled study, the team examined the vaccine’s safety, tolerability and immune responses in HIV-positive adults between the ages of 18 and 50.

The participants were divided into two groups: One received the vaccine, and the other a placebo. They recorded any adverse effects in a diary a week after the injection. After that, they were examined at the test site on weeks 4, 6, 12, 18, 26 and 52 after the vaccination. There was no evidence of serious adverse effects in the trial.

The vaccine showed promise in its ability to prompt the immune system. Researchers found that, following vaccination, the antibody against HIV’s p24 capsid antigen increased by a factor as great as 64 and the antibody against the virus’s gp120 surface antigen rose up to eightfold. These levels remained elevated throughout the yearlong study period.

“We are now prepared to take the next steps toward Phase II and Phase III clinical trials,” said Jung-Gee Cho, CEO of Sumagen. “We are opening the gate to pharmaceutical companies, government and charity organization [sic] for collaboration to be one step closer to the first commercialized HIV vaccine.”

To read the Huffington Post story, click here.

To read the Western University press release, click here.

Search: HIV, vaccine, Phase I, Sumagen Canada Inc., Western University, Jung-Gee Cho, Huffington Post.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:

  comments 1 - 1 (of 1 total)    

bob, south Africa, 2013-09-18 13:20:40
when does the vaccine will be sold or gave to peoples?

comments 1 - 1 (of 1 total)    

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.